ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
Company profile
Ticker
SLRN
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
852406735
SLRN stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
S-8
Registration of securities for employees
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
28 Mar 24
8-K
Rapid improvements demonstrated for proptosis, clinical activity scores, and diplopia versus placebo with a favorable safety profile
20 Mar 24
8-K
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
11 Mar 24
8-K
Departure of Directors or Certain Officers
20 Dec 23
8-K
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
27 Nov 23
Transcripts
Latest ownership filings
SC 13G
INTEGRATED CORE STRATEGIES (US) LLC
19 Apr 24
4
Shao-Lee Lin
3 Apr 24
SC 13G
AyurMaya Capital Management Company, LP
28 Mar 24
144
Notice of proposed sale of securities
20 Mar 24
4
Shao-Lee Lin
22 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Shao-Lee Lin
11 Jan 24
4
Ronald Oyston
11 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 381.74 mm | 381.74 mm | ||||
Cash burn (monthly) | 58.14 mm | 31.47 mm | ||||
Cash used (since last report) | 395.90 mm | 214.31 mm | ||||
Cash remaining | -14.16 mm | 167.43 mm | ||||
Runway (months of cash) | -0.2 | 5.3 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 109 |
Opened positions | 51 |
Closed positions | 26 |
Increased positions | 20 |
Reduced positions | 23 |
13F shares | Current |
---|---|
Total value | 822.55 bn |
Total shares | 98.69 mm |
Total puts | 525.60 k |
Total calls | 167.97 k |
Total put/call ratio | 3.1 |
Largest owners | Shares | Value |
---|---|---|
Westlake BioPartners Fund II | 9.79 mm | $241.73 mm |
AyurMaya Capital Management | 9.33 mm | $94.93 bn |
FMR | 8.96 mm | $89.91 bn |
Citadel Advisors | 5.93 mm | $57.89 bn |
Orbimed Advisors | 5.33 mm | $54.17 bn |
Ai Acel | 5.10 mm | $125.82 mm |
Opaleye Management | 4.15 mm | $42.17 bn |
venBio Partners | 3.85 mm | $39.18 bn |
Vanguard | 3.19 mm | $32.43 bn |
JPM JPMorgan Chase & Co. | 3.16 mm | $32.18 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Lin Shao-Lee | Common Stock | Sell | Dispose S | No | No | 6.6283 | 9,961 | 66.02 k | 1,577,374 |
20 Feb 24 | Lin Shao-Lee | Common Stock | Sell | Dispose S | No | No | 7.6048 | 15,701 | 119.40 k | 1,587,335 |
9 Jan 24 | Labrucherie Gil M | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 7.68 | 855,513 | 6.57 mm | 855,513 |
9 Jan 24 | Melanie Gloria | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 7.68 | 494,297 | 3.80 mm | 494,297 |
9 Jan 24 | Mina Kim | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 7.68 | 190,114 | 1.46 mm | 190,114 |
News
HC Wainwright & Co. Reiterates Buy on Acelyrin, Maintains $28 Price Target
1 Apr 24
Acelyrin Q4 EPS $(0.75) Beats $(0.99) Estimate
28 Mar 24
Wells Fargo Maintains Equal-Weight on Acelyrin, Raises Price Target to $13
21 Mar 24
Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients
20 Mar 24
HC Wainwright & Co. Reiterates Buy on Acelyrin, Maintains $30 Price Target
20 Mar 24
Press releases
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
27 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
11 Mar 24
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
11 Mar 24